Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor protein—may play a role in Alzheimer’s disease.

A newly identified role for the neuronal MPS shows it controls nutrient uptake by acting as a gatekeeper. Its disruption ...

Researchers have dosed the first participant in a clinical trial of an investigational medicine designed to lower the amount of amyloid precursor protein (APP) for the potential treatment of Alzheimer ...

Alzheimer's disease (AD) is a neurodegenerative disease that causes progressive memory loss and a significant decline in ...

A new King’s College London study finds a cancer drug may reverse brain connectivity changes linked to early Alzheimer’s ...

Lactylation, a recently identified post-translational modification, has emerged as important for immune regulation, tissue repair, cancer cell metabolism, and now, potentially, Alzheimer’s disease. In ...

Cerebrospinal fluid (CSF) is a clear and watery liquid that flows in and around the brain and spinal cord. Its functions include protecting parts of the nervous system, delivering nutrients and ...

– First Patient Dosed in Multiple-dose Part B Portion of Study, with the Study Proceeding in Canada, UK, and the Netherlands – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq ...

Billions of dollars have been spent on Alzheimer's drugs that target Amyloid beta. While companies developing drugs to treat Alzheimer’s disease have spent decades and many billions of dollars ...

While billions of dollars have been spent targeting Amyloid beta (Aβ) in Alzheimer’s patients, a newly reevaluated, shorter peptide known as P3 forms toxic clumps faster than Aβ and may also ...